Ravi K Amaravadi

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician , Hospital of the University of Pennsylvania
Member, Institute of Translational Medicine and Therapeutics
Member, Abramson Cancer Center
Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
Co-Leader Cancer Therapeutics Program , Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Hematology-Oncology Division
University of Pennsylvania
16 Penn Tower
3400 Spruce St.
Philadelphia, PA 19104
Office: 215-662-7402
Fax: 215-349-8550
BA (Biochemistry )
Columbia University , 1996.
MD (Medicine)
Johns Hopkins University , 2000.
Permanent link

Description of Research Expertise

Autophagy, Mechanisms of Cell Death, Developmental Therapeutics

Description of Itmat Expertise

Dr. Amaravadi conducts basic, preclinical and Phase I/II clinical trials in novel molecularly targeted therapeutics and combinations in cancer therapy.

Selected Publications

Twyman-Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, Xu B, Dada H, Odiorizzi P, Herati R, Mansfield K, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma D, Xu X, Feldman M, Gangadhar T, Hahn S, Wherry JE, Vonderheide R, Benci J, Minn A. : Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer. Nature Mar 2015 Notes: [Epub ahead of print]

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.: A Phase 1 Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics Sept 2015.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.: Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research Jul 2015.

Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. : Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The Oncologist June 2015.

Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, Liu R, Li L, Amaravadi RK, Xu W, Karakousis GC, Gangadhar TC, Schuchter LM, Lieu M, Khare S, Halloran MB, Herlyn M, Kaufman RE: BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res. Jan epub 2015.

Krayya A, Piao S, Xu G, Zhang G, Gimotty PG, Xu X, Amaravadi RK**, Speicher DW**. **Co-senior authors.: Identification of secreted proteins that reflect autophagy dynamics with tumor cells Autophagy 11(1): 60-74, Jan 2 2015.

Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB.: Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer 51(11): 1435-43, 2015.

Kong J, Whelan KA, Laczkó D, Dang B, Caro Monroig A, Soroush A, Falcone J, Amaravadi RK, Rustgi AK, Ginsberg GG, Falk GW, Nakagawa H, Lynch JP.: Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. . PMID: 26373456 Molecular Carcinogenesis doi: 10.1002/mc.22406. , 2015.

Liu S, Tetzlaff MT, Wang T, Yang R, Xie L, Zhang G, Krepler C, Xiao M, Beqiri M, Xu W, Karakousis G, Schuchter L, Amaravadi RK, Xu W, Wei Z, Herlyn M, Yao Y, Zhang L, Wang Y, Zhang L, Xu X.: miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment Cell and Melanoma Research 28(4): 431-41, 2015.

Hubbard-Lucey V, Shono Y,Maurer K,West ML,Singer NV, Ziegler CG, Lezcano, C, Motta AC,Schmid K,Levi SM,Murphy GF,Liu C,Winkler JD,Amaravadi JK,Rogler G,Dickinson AM,Holler E,van den Brink M,Cadwell K: Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity Page: http://dx.doi.org/10.1016/j.immuni.2014.09.011, Dec 2014.

back to top
Last updated: 04/15/2016
The Trustees of the University of Pennsylvania